CureVac
CVAC
Market cap $633M

2.82 USD

-0.02

0.70%

At close Oct 17, 4:00 PM EDT

After hours

2.82

+0.00

0.00%

1 day

-0.70%

5 days

-1.74%

1 month

-14.02%

3 months

-22.74%

6 months

9.73%

Year to date

-32.70%

1 year

-51.38%

5 years

-94.96%

About: CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

Employees: 1,100

0

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

74% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 19

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

10% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 21

1.73% less ownership

Funds ownership: 8.03% [Q1] → 6.3% (-1.73%) [Q2]

2% less funds holding

Funds holding: 87 [Q1] → 85 (-2) [Q2]

15% less capital invested

Capital invested by funds: $56.3M [Q1] → $48M (-$8.35M) [Q2]

58% less call options, than puts

Call options by funds: $839K | Put options by funds: $2.01M

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$16

467%

upside

Avg. target

$16

467%

upside

High target

$16

467%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

JMP Securities Roy Buchanan 26% 1-year accuracy 5 / 19 met price target	467%upside $16	Market Outperform Reiterated	16 Sept 2024
JMP Securities Roy Buchanan 26% 1-year accuracy 5 / 19 met price target	467%upside $16	Market Outperform Maintained	16 Aug 2024

See Analyst Rankings

Financial journalist opinion

Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents

Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's High Court.

Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents

CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy 84% of immune responses were de novo, observed in patients without pre-existing T-cell activity against encoded cancer antigens CVGBM was generally well tolerated up to the highest tested dose level of 100 µg with no dose-limiting toxicities Most common adverse events were mild to moderate systemic reactions such as headache, fever and chills, which resolved within 1-2 days post injection 100 µg was selected as the recommended dose for the dose expansion phase, which recently started enrollment TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 13, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today presented compelling data from the dose-escalation Part A of its ongoing Phase 1 CVGBM cancer vaccine study in patients with glioblastoma at the European Society for Medical Oncology (ESMO) Congress.

CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program

Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all pre-defined study endpoints Vaccine candidate based on CureVac's proprietary second-generation mRNA backbone GSK confirmed data support advancing program to Phase 3; dosing of first Phase 3 participant is associated with a significant milestone payment for CureVac In July 2024, GSK assumed full control for the development, manufacturing and commercialization of influenza vaccines through new licensing agreement TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 12, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that GSK has reported positive Phase 2 headline data from the seasonal influenza mRNA vaccine program.

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 9, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the first clinical data from CureVac's ongoing Phase 1 CVGBM cancer vaccine study in patients with resected glioblastoma will be presented at the European Society for Medical Oncology (ESMO) Congress (Barcelona, Spain, September 13-17, 2024).

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

Closed new licensing agreement with GSK worth up to €1.45 billion, including €400 million upfront; provides strong validation of CureVac's mRNA platform Initiated strategic workforce reduction of ~30% by end of 2024, optimizing business to focus on high-value opportunities in oncology, infectious diseases and other areas Invoiced €10 million milestone payment after Phase 2 transition of pre-pandemic avian influenza (H5N1) program; candidate fully licensed to GSK under new agreement Dosing of first patient in Phase 1 study Part B in glioblastoma with CVGBM to establish dose-confirmation; initial dose-escalation Part A data accepted for oral presentation at ESMO Strengthening of Supervisory Board with appointment of innovation expert Birgit Hoffman and clinical oncologist Mehdi Shahidi, M.D. Chief Financial Officer, Pierre Kemula, to step down at the end of his term October 31, 2024; search for a replacement ongoing with transition plan in place Cash and cash equivalents position of €202.5 million as of June 30, 2024, not including €400 million upfront payment from GSK agreement; reaffirming cash runway into 2028 TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V.

CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update

CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBM Part B expected to include up to 20 patients to generate extended data on safety, tolerability, and immunogenicity of CVGBM TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the start of the dose-confirmation Part B of its ongoing Phase 1 study in patients with resected glioblastoma.

CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board

TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today named clinical oncologist Mehdi Shahidi, M.D.

CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board

Zacks Investment Research

CureVac N.V. (CVAC) Expected to Beat Earnings Estimates: Should You Buy?

CureVac (CVAC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CureVac N.V. (CVAC) Expected to Beat Earnings Estimates: Should You Buy?

Zacks Investment Research

CureVac (CVAC) Upgraded to Buy: What Does It Mean for the Stock?

CureVac (CVAC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CureVac (CVAC) Upgraded to Buy: What Does It Mean for the Stock?

CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech

New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent litigation UK trial on validity of intellectual property rights EP 3 708 668 B1 and EP 4 023 755 B1 (split poly-A tail technology) began July 10; judgement expected later in 2024 TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 11, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the latest trial dates for its ongoing patent litigation against Pfizer/BioNTech in multiple geographies including the U.S., UK and Germany.

CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech

See News Rankings

Charts implemented using Lightweight Charts™